I agree with your statements. Nothing personal for/against NP, but thank goodness leronlimab is the real deal and IMHO will be what ultimately determines CYDY value. That is why I am here and likely most others. NP will likely be replaced one day, but leronlimab will be used long after (and eventually generic versions) to help save many lives! This should make a very well rewarded investment for all of us at some point in the relatively near future regardless of NPs strengths and weaknesses (IMHO, I can't see anything derailing the leronlimab train with its superior safety profile, lack of resistance, negligible toxicity and being this close to HIV approval given how far it has traveled to get to this point, and if cancer results are as positive as they sound and I expect, NASH, mono, PrEP, GvHD, MS, COPD or anything else being successful is only icing on the cake).